 |
 |
|||||||
Showcase your company to over 8000 key decision makers worldwide within the pharmaceutical and biotech sectors.Pharmaceutical and biotechnology executives refer to the Drug Delivery Report (DDR) throughout the year as the main method of independently assessing drug delivery partners.
If you want to complete a deal in 2006, then advertising in the Drug Delivery Report Spring/Summer 2006 and on drugdeliveryreport.com is a must. Contact Sarah O'Connell on +44 (0) 1865 784 177 or e-mail enquiries@pharmaventures.com to find out how you can promote your company. Copy Deadline: Friday 31st March 2006 |
||||||||
 |
 |
|||||||
 |
Market News and TrendsDuring February 2006, PharmaDeals Agreements recorded 18 deals that related to drug delivery. The majority of the deals were either between two start-up companies (6 in total) or between an established and a start-up company (also 6 in total). These deals focused upon licensing, technology access, evaluation and funding, collaborative R&D and marketing agreements. A variety of drug delivery systems were represented in February's deals, including patches, a gel and liquid spray, an aerosol pump, vaccines, nasal powder and medical devices. Arguably, of most note during February 2006 were the five deals in which start-up and emerging companies agreed to work with US academic or government bodies in order to research and develop highly innovative and novel methods of drug delivery. Read more... |
||
|
|
||
Featured ArticleRecent Trends in Oral Drug DeliveryOral drug delivery remains the most user-friendly form of drug delivery, having the highest degree of patient compliance, and is still the preferred route of drug administration. As such, drugs for chronic conditions are often administered orally for ease of long-term use. In his technical overview, Jason McConville, of the College of Pharmacy at the University of Texas at Austin, aims to provide a brief summary of some of the current innovative research areas in oral drug delivery. He focuses on improved drug dissolution, absorption enhancement, novel controlled-release formulations and innovations in GI targeting. Read more... |
 |
||
|
|
||
 |
Company ProfilesAegis Therapeutics, Alkermes, Flamel Technologies, Ypsomed |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Water-based Nanotechnology for Improved Drug Delivery Administrative Route - Multiple administration routes Indication - Solubilisation of hydrophobic, insoluble molecules and compounds Licence code LO-0306-01 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Spring / Summer 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz